Silo Pharma, Inc. (SILO) AI Stock Analysis
SILO AI stock analysis summary
AI ResearchSilo Pharma, Inc. (SILO) is a developmental-stage biopharmaceutical firm focusing on integrating traditional therapeutics with psychedelic research. The company generated $54,077 in trailing twelve-month revenue alongside an operating margin of -8250.5%. As of June 30, 2026, Silo held $5.4M in cash and short-term investments.
- Market cap
- $2.4M
- Revenue (TTM)
- $54,077
- P/E
- —
- 1Y return
- -86.9% S&P 500 16.8%
- Avg. target
- $10.00 747.5% vs last close
Bull case
- Silo Pharma held $5.4M in cash and short-term investments as of June 30, 2026, providing a liquid buffer against total assets of $6.0M.
- The company maintains a high liquidity buffer with a current ratio of 5.36 as of the quarter ended June 30, 2026.
- Wall Street analysts set a mean price target of $10.00, which reflects potential upside of 747.5% compared to the October 16, 2026 closing price of $1.18.
Bear case
- The company's operating margin stood at -8250.5% over the trailing twelve months, reflecting sustained losses relative to its $54,077 in revenue.
- Free cash flow in FY2025 was -$4.7M, driven by continued operational cash burn alongside capital expenditures of $574,920.
- Shareholders have faced substantial dilution, evidenced by a 758.9% expansion in share count over the trailing five years.
What Silo Pharma does
Silo Pharma, Inc., a biopharmaceutical company in the developmental stage, is dedicated to pioneering treatments that integrate traditional therapeutics with cutting-edge psychedelic research. The company focuses on addressing unmet medical needs by exploring the potential of psychedelic drugs, such as psilocybin, in treating conditions that have been historically underserved. Silo Pharma aims to acquire and develop intellectual property and technology rights from universities and researchers to advance therapies for rare diseases, with a particular emphasis on depression, mental health disorders, and various neurological conditions, including post-traumatic stress disorder (PTSD), Alzheimer's disease, and Parkinson's disease. The Englewood Cliffs, New Jersey-based company operates with 3 employees.
Growth and profitability
Silo Pharma recorded annual revenue of $71,264 in FY2021 before reporting flat revenue of $72,102 in each fiscal year from FY2022 through FY2025. Gross margin shifted from 91.9% in FY2024 to -1128.9% in FY2025. Operating margin remained deeply negative, landing at -5937.0% in FY2025 with an annual net income of -$4.2M. For the trailing twelve months ending June 30, 2026, revenue stood at $54,077 with an operating margin of -8250.5% and diluted earnings per share of -$4.26.
Balance sheet and cash flow
As of June 30, 2026, Silo Pharma reported $5.4M in cash and short-term investments, total assets of $6.0M, and shareholders' equity of $4.9M. Its current ratio stood at 5.36. Free cash flow was -$4.7M in FY2025, matching its operating cash flow of -$4.7M. Capital expenditures totaled $574,920 in FY2025, while the company's share count increased 758.9% over five years.
Valuation and performance
At a share price of $1.18, Silo Pharma has a market capitalization of $2.4M and an enterprise value of -$2.3M. The stock trades at a price-to-sales multiple of 44.8x, compared to the median of 4.1x for its US-listed Healthcare peers. Its price-to-book ratio is 0.6x, and its EV-to-EBITDA is 0.6x versus the US-listed Healthcare median of 12.0x. Over the past year, SILO returned -86.9%, lagging the S&P 500 (SPY) return of 16.8%.
What analysts expect
Analysts maintain a mean price target of $10.00 for Silo Pharma, representing 747.5% upside from the last closing price of $1.18. Over the trailing four quarters, the company delivered 0 EPS beats. The next scheduled earnings date is November 12, 2026.
Key risks and what to watch
- Annual operating cash flow stood at -$4.7M in FY2025, which draws steadily against the $5.4M in cash and short-term investments held as of June 30, 2026.
- The company posted zero EPS beats over the last 4 quarters, highlighting consistent earnings misses.
- The stock is trading 75.3% below its 200-day moving average and recorded a 1-year return of -86.9%.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this SILO AI stock analysis
This page is an AI-written research summary of Silo Pharma, Inc. (SILO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: SILO income statement, SILO balance sheet, SILO key metrics, SILO chart. See the SILO stock overview for the latest quote and news.
SILO AI stock analysis FAQ
What does Silo Pharma do?
Silo Pharma, Inc. is a developmental-stage biopharmaceutical firm working on treatments that merge traditional therapeutics with psychedelic research, specifically targeting conditions like depression, PTSD, Alzheimer's disease, and Parkinson's disease.
What is Silo Pharma's valuation and market capitalization?
As of October 16, 2026, Silo Pharma had a market capitalization of $2.4M, an enterprise value of -$2.3M, and a price-to-sales ratio of 44.8x.
Does Silo Pharma pay a dividend?
No, Silo Pharma does not currently pay a dividend to shareholders.
What is the analyst price target for SILO?
Analysts have set a mean price target of $10.00, which sits 747.5% above the stock's closing price of $1.18 on October 16, 2026.